Search by product name, CAS, target or catalog number. Press Down Arrow to reach product suggestions, Tab to move between links, and Escape to close suggestions.
Ras inhibitors and related small GTPase modulators act on KRAS and on the Rac, Rho and Cdc42 proteins. Small GTPases of the Ras superfamily work as molecular switches. They cycle between an active form bound to guanosine triphosphate (GTP) and an inactive form bound to guanosine diphosphate (GDP). Oncogenic KRAS mutations such as G12C keep the protein in its signaling state. ARS-853 and KRas G12C inhibitor 4 target the mutant cysteine of KRAS G12C, while Kobe2602 interferes with binding of Ras to Raf. Salirasib, a farnesylcysteine mimetic, disrupts the membrane association of Ras. Rho-family tools include NSC 23766 and EHT 1864, which inhibit Rac, and CASIN, which targets Cdc42.
JH530 is a potent inducer of methuosis, specifically targeting triple-negative breast cancer (TNBC) cells. It triggers extensive intracellular vacuolization, leading to the inhibition of TNBC cell proliferation. With its demonstrated anti-tumor activity, JH530 serves as a valuable tool for cancer research applications.
KARS-IN-1 is a potent inhibitor of lysyl-tRNA synthetase (KARS), specifically dependent on AKR1C3, with an AC50 of 9.1 nM for human KARS. This compound exhibits anti-proliferative effects in H460 cells, featuring high AKR1C3 expression, and in Hara cells, which have low AKR1C3 expression, with AC50 values of 21 nM and 16 nM, respectively. KARS-IN-1 is valuable for research focused on non-small cell lung cancer (NSCLC) and the therapeutic targeting of KARS in cancer biology.
Out of stock
All 3 sizes
CE3F4 analog 1 is a structural analogue of CE3F4, specifically designed to target and modulate the same biochemical pathways. This compound exhibits potential biological activity that can be leveraged in research to understand its pharmacological effects and therapeutic applications. CE3F4 analog 1 is useful in studies focused on drug development and the exploration of cellular signaling mechanisms.
pan-KRAS-IN-4 is a highly potent KRAS inhibitor, demonstrating IC50 values of 0.37 nM for KRAS G12C and 0.19 nM for KRAS G12V. Its specific mechanistic action targets mutated KRAS proteins, making it a valuable tool for studying oncogenic signaling pathways. This compound is particularly relevant for research applications focused on cancer biology, therapeutic development, and the exploration of KRAS-related malignancies.
Out of stock
All 3 sizes
KRAS G12C inhibitor 34 is a selective inhibitor targeting the KRAS G12C mutation, a common driver in various cancers. This compound demonstrates significant anticancer activity by disrupting KRAS signaling pathways, leading to reduced cell proliferation. It is suitable for research applications focusing on cancer biology, particularly in the development and evaluation of targeted therapies for KRAS-driven tumors.
Out of stock
All 3 sizes
KRAS G12C Inhibitor 68 is a selective inhibitor targeting the KRAS G12C mutation, with an IC50 of 7 nM. It exhibits significant anti-tumor activity, making it a valuable tool for cancer research, particularly in studies focused on KRAS-driven malignancies. This compound is suitable for investigating the efficacy of KRAS-targeted therapies and understanding the underlying mechanisms of KRAS-related tumorigenesis.
Out of stock
All 3 sizes
CFL-120 is a potent inhibitor of the KRasG12C protein. It exhibits significant antiproliferative effects and demonstrates anticancer activity, making it a valuable tool for cancer research. CFL-120 is particularly relevant for studies focused on lung cancer therapeutics.
(R)-ACBI-4 is a selective PROTAC degrader targeting the GTP-loaded active state of KRAS (KRAS(on)). It exhibits notable anti-proliferative activity and effectively degrades various KRAS mutants, including KRASG12R, in cancer cell lines. This compound is utilized in research focused on understanding KRAS-driven oncogenesis and therapeutic interventions in KRAS-related cancers.
Out of stock
All 3 sizes
KRAS G12D Inhibitor 7 is a selective small molecule targeting the KRAS G12D mutation, which is commonly associated with various cancers. This compound demonstrates potent inhibitory activity against KRAS G12D-driven signaling pathways, making it a valuable tool for cancer research, particularly in studies focused on targeted therapies and drug resistance mechanisms. Its specificity for KRAS G12D highlights its potential in elucidating the role of this mutation in tumorigenesis and therapeutic response.
KRAS G12C inhibitor 42 is a selective inhibitor targeting the KRAS G12C mutation, a key driver of various cancers. This compound demonstrates significant anti-cancer activity by disrupting KRAS signaling pathways involved in tumor growth and proliferation. KRAS G12C inhibitor 42 is suitable for research applications focused on KRAS G12C-mediated malignancies and may aid in the development of targeted cancer therapies.
KRAS G12D inhibitor 16 is a selective inhibitor targeting the KRAS G12D mutation, demonstrating potent inhibitory activity with IC50 values of 0.7 nM against KRAS G12D and 0.35 μM against other KRAS G12D variants. This compound is valuable for research into various malignant tumors, including pancreatic ductal adenocarcinoma (PDAC), colon and rectal carcinomas (CRC), and non-small cell lung carcinoma (NSCLC). Its efficacy positions it as a significant tool for investigating KRAS-driven oncogenic pathways and therapeutic strategies.
SOF-436 is a selective KRAS inhibitor that targets SOS1-mediated nucleotide exchange, exhibiting an IC50 of 60 μM. Additionally, it effectively disrupts the interaction between KRAS and the effector protein RAF. This compound is primarily utilized in cancer research, providing insights into KRAS-driven oncogenic pathways.
Out of stock
All 3 sizes
KRAS inhibitor-36 is a selective inhibitor targeting the KRAS Q61H mutant protein. This compound effectively interferes with KRAS signaling pathways, leading to reduced cellular proliferation and survival in KRAS-dependent cancer models. It is primarily utilized in research aimed at elucidating KRAS-related oncogenic mechanisms and developing novel therapeutic strategies for KRAS-driven malignancies.
KRAS G12C inhibitor 54 is a selective inhibitor targeting the KRAS G12C mutant protein. This compound demonstrates potent inhibition of KRAS G12C-mediated signaling pathways, leading to reduced cellular proliferation in KRAS G12C-driven tumor models. It is primarily used in cancer research, particularly for studying therapeutic strategies against KRAS G12C mutations in various malignancies.
Out of stock
All 3 sizes
(S,R,S)-BBO-11818 is a selective inhibitor of KRAS, a key oncogenic driver in various cancers. This compound is instrumental in elucidating the role of KRAS in tumorigenesis and has potential applications in developing targeted therapies for KRAS-driven malignancies. It serves as a valuable tool for researchers investigating KRAS signaling pathways and their implications in cancer biology.
Out of stock
All 3 sizes
pan-KRAS-IN-16 is a potent RAS inhibitor that disrupts protein-protein interactions involving RAS effector proteins. This small molecule, derived from an intracellular antibody fragment, binds to a hydrophobic pocket adjacent to the effector-binding switch regions of RAS. By inhibiting these interactions, pan-KRAS-IN-16 effectively blocks endogenous RAS-dependent signaling in tumor cell lines, making it a valuable tool for research in cancer biology and therapeutic development targeting RAS mutation-driven malignancies.
KRAS G12C Inhibitor 31 is a selective inhibitor targeting the KRAS G12C mutation, which plays a critical role in cancer pathogenesis. This compound demonstrates potent inhibitory activity, making it a valuable tool for research into KRAS-driven malignancies. It is suitable for studies focused on cancer therapeutics and mechanisms of KRAS-associated signaling pathways.
Synonyms: 8-(4-Methoxyphenylthio)-2'-O-Me-cAMP
8-pMeOPT-2'-O-Me-cAMP is a cAMP analogue that selectively activates exchange proteins directly activated by cAMP (Epac) without stimulating protein kinase A (PKA). This compound serves as an important tool in research applications aimed at dissecting the role of cAMP signaling pathways. Its unique properties make it useful for studying Epac-related functions and mechanisms in various cellular contexts.
KRAS inhibitor-38 is a selective inhibitor targeting KRAS mutations, specifically KRAS G12C, KRAS G12D, and KRAS G12V. This compound effectively suppresses the activity of these mutant KRAS proteins in vivo, making it a valuable tool for research on KRAS-driven cancers. It is applicable in studies investigating the role of KRAS in tumorigenesis and potential therapeutic strategies for targeting KRAS mutations.
Out of stock
All 3 sizes
KRAS G12C-IN-71 is a covalent inhibitor targeting the G12C mutation of the KRAS protein, exhibiting a Ki of 380 nM. This compound demonstrates significant biological activity by selectively inhibiting mutant KRAS, making it a valuable tool for research in non-small cell lung cancer. Its application aids in understanding the role of KRAS mutations in cancer progression and therapeutic strategies.
Out of stock
All 3 sizes
KRAS G12C-IN-70 is a selective inhibitor that targets the KRAS G12C mutant, effectively disrupting downstream signaling pathways such as RAF-MEK-ERK. This inhibition leads to a reduction in tumor cell proliferation, making KRAS G12C-IN-70 a valuable tool for research into tumors associated with the KRAS G12C mutation, including non-small cell lung cancer and colorectal cancer. Researchers investigating the therapeutic potential of targeting KRAS G12C will find this compound particularly useful.
Out of stock
All 3 sizes
SS-3091 is a pan KRas inhibitor that targets the interaction interfaces of KRas, leading to the destabilization of the ARaf/KRas complex and modulation of downstream signaling pathways. This compound exhibits significant anticancer and antiproliferative effects against various KRas mutant forms, including G12D, G12C, G12V, and G12S, in a range of cancer cell lines. SS-3091 is valuable for research into KRas-mediated signaling and its implications in cancer biology.
BIM-46068 is a selective inhibitor of human brain Farnesyltransferase (FTase) with an IC50 of 91.4 nM. This compound effectively inhibits Ras processing in MiaPaCa-2 cancer cells, making it a valuable tool for research on pancreatic cancer. Its ability to specifically target FTase positions BIM-46068 as an important reagent for exploring the molecular mechanisms underlying Ras signaling in cancer.
KRAS Inhibitor-17 is a selective inhibitor targeting the KRAS G12C oncogenic mutation, exhibiting an IC50 of 3.37 µM. It effectively inhibits phosphorylated ERK (p-ERK) with IC50 values of 9.25 µM in MIA PaCA-2 cells and >33.3 µM in A549 cells. This compound holds promise for advancing research in pancreatic, colorectal, and lung cancers, contributing to the understanding of KRAS-driven tumorigenesis.
DCAI is a Ras protein binder that specifically inhibits Ras activation and nucleotide exchange facilitated by SOS. This compound is valuable for studying cancer associated with mutations in the Ras gene, providing insight into the molecular mechanisms underlying Ras-driven tumorigenesis. DCAI serves as an essential tool for researchers investigating targeted therapies for Ras-related cancers.
